Tollefson MK - Search Results

1

Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome.

Schneider SA, Sukov WR, Frank I, Boorjian SA, Costello BA, Tarrell RF, Thapa P, Houston Thompson R, Tollefson MK, Jeffrey Karnes R, Cheville JC. Schneider SA, et al. Among authors: tollefson mk. Mod Pathol. 2014 May;27(5):758-64. doi: 10.1038/modpathol.2013.201. Epub 2013 Nov 1. Mod Pathol. 2014. PMID: 24186136 Free article.

2

Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other.

Tollefson MK, Thompson RH, Sheinin Y, Lohse CM, Cheville JC, Leibovich BC, Kwon ED. Tollefson MK, et al. Cancer. 2007 Aug 15;110(4):783-90. doi: 10.1002/cncr.22840. Cancer. 2007. PMID: 17594714 Free article.

3

Functional and oncological outcomes after orthotopic neobladder reconstruction in women.

Granberg CF, Boorjian SA, Crispen PL, Tollefson MK, Farmer SA, Frank I, Blute ML. Granberg CF, et al. Among authors: tollefson mk. BJU Int. 2008 Dec;102(11):1551-5. doi: 10.1111/j.1464-410X.2008.07909.x. Epub 2008 Oct 8. BJU Int. 2008. PMID: 18990170

4

Long-term outcome of ureterosigmoidostomy: an analysis of patients with >10 years of follow-up.

Tollefson MK, Elliott DS, Zincke H, Frank I. Tollefson MK, et al. BJU Int. 2010 Mar;105(6):860-3. doi: 10.1111/j.1464-410X.2009.08811.x. Epub 2009 Aug 13. BJU Int. 2010. PMID: 19681892

5

The effect of Gleason score on the predictive value of prostate-specific antigen doubling time.

Tollefson MK, Blute ML, Rangel LJ, Bergstralh EJ, Boorjian SA, Karnes RJ. Tollefson MK, et al. BJU Int. 2010 May;105(10):1381-5. doi: 10.1111/j.1464-410X.2009.08976.x. Epub 2009 Oct 26. BJU Int. 2010. PMID: 19863524

6

Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma.

Tollefson MK, Blute ML, Farmer SA, Frank I. Tollefson MK, et al. J Urol. 2010 Jan;183(1):81-6. doi: 10.1016/j.juro.2009.08.158. J Urol. 2010. PMID: 19913820

7

Raman spectral imaging of prostate cancer: can Raman molecular imaging be used to augment standard histopathology?

Tollefson M, Magera J, Sebo T, Cohen J, Drauch A, Maier J, Frank I. Tollefson M, et al. BJU Int. 2010 Aug;106(4):484-8. doi: 10.1111/j.1464-410X.2010.09185.x. Epub 2010 Mar 1. BJU Int. 2010. PMID: 20201840

8

The impact of family history on pathological and clinical outcomes in non-syndromic clear cell renal cell carcinoma.

Tollefson MK, Boorjian SA, Lohse CM, Blute ML, Leibovich BC. Tollefson MK, et al. BJU Int. 2010 Dec;106(11):1638-42. doi: 10.1111/j.1464-410X.2010.09441.x. BJU Int. 2010. PMID: 20553256

9

Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy.

Tollefson MK, Blute ML, Rangel LJ, Karnes RJ, Frank I. Tollefson MK, et al. J Urol. 2010 Sep;184(3):925-9. doi: 10.1016/j.juro.2010.05.043. J Urol. 2010. PMID: 20643452

10

Long-term complications of conduit urinary diversion.

Shimko MS, Tollefson MK, Umbreit EC, Farmer SA, Blute ML, Frank I. Shimko MS, et al. Among authors: tollefson mk. J Urol. 2011 Feb;185(2):562-7. doi: 10.1016/j.juro.2010.09.096. Epub 2010 Dec 18. J Urol. 2011. PMID: 21168867

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

170 results

Search Page

Filters